Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said

You may also be interested in...



AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis

HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC067399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel